心脏起搏器患者的心力衰竭超声心动图筛查与照护路径优化:一项随机对照试验
OPT-PACE多中心对照试验将1201例起搏器患者随机分为超声心动图筛查组或常规照护组。筛查组600例中201例(34%)检出左心室收缩功能障碍(LVSD)。中位31个月随访期间,筛查组主要复合终点(首次心衰住院或死亡)发生106/600例(18%),常规照护组115/601例(19%),无显著差异(HR=0.89;95%CI 0.69,1.17)。
要点
- 超声心动图筛查在起搏器患者中常检出LVSD(34%)。
- 筛查组主要终点18% vs 常规照护组19%,无显著差异(HR=0.89;95%CI 0.69,1.17)。
- 预设非随机探索性分析中,由专科心衰与器械门诊管理的LVSD患者主要终点事件少于初级保健管理。
核心结论
- 超声心动图筛查在起搏器患者中常检出LVSD,但单纯筛查并未改变临床结局。
研究设计与样本
- 多中心对照试验(OPT-PACE),将1201例起搏器患者(717例男性)随机分配至超声心动图筛查组或常规照护组。
主要发现
- 筛查组600例中201例(34%)检出LVSD。
- 中位31个月(四分位距30-40个月)随访期间,筛查组主要复合终点(首次心衰住院或死亡时间)发生106/600例(18%),常规照护组发生115/601例(19%),无显著差异(HR=0.89;95%CI 0.69,1.17)。
- 预设非随机探索性分析中,由专科心衰与器械门诊管理的LVSD患者主要终点事件少于初级保健管理。
关键数值与推荐
- 主要复合终点:首次心衰住院或死亡时间。
- 筛查组主要终点106/600例(18%)vs 常规照护组115/601例(19%)(HR=0.89;95%CI 0.69,1.17),无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with pacemakers are at increased risk of left ventricular systolic dysfunction (LVSD). Whether screening for and optimizing the medical management of LVSD in these individuals can improve clinical outcomes is unknown. In the present study, in a multicenter controlled trial (OPT-PACE), we randomized 1,201 patients (717 men) with a pacemaker to echocardiography screening or usual care. In the screening arm, LVSD was detected in 201 of 600 (34%) patients, who then received management in either primary care or a specialist heart failure (HF) and devices clinic. The primary outcome of the trial was the difference in a composite of time to first HF hospitalization or death. Over 31 months (interquartile range = 30-40 months), the primary outcome occurred in 106 of 600 (18%) patients receiving echocardiography screening, which was not significantly different compared with the occurrence of the primary outcome in 115 of 601 (19%) patients receiving the usual care (hazard ratio = 0.89; 95% confidence interval = 0.69, 1.17). In a prespecified, nonrandomized, exploratory analysis, patients with LVSD managed by the specialist clinic experienced the primary outcome event less frequently than those managed in primary care. The results of this trial indicate that echocardiography screening commonly identifies LVSD in individuals with pacemakers but alone does not alter outcomes. ClinicalTrials.gov registration: NCT01819662 .
引用
- Paton MF, Gierula J, Jamil HA, et al. Echocardiographic screening for heart failure and optimization of the care pathway for individuals with pacemakers: a randomized controlled trial. Nat Med. 2024. PMID: 39300290. doi:10.1038/s41591-024-03265-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。